Raymond James & Associates’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Raymond James & Associates’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,802	Closed	-$76K	–	3554
2017 Q2	$76K	Buy	7,802 +967	+14%	+$19.8K	﹤0.01%	3147
2017 Q1	$166K	Buy	6,835 +1,209	+21%	+$30.2K	﹤0.01%	2977
2016 Q4	$181K	Sell	5,626 -318	-5%	-$13.6K	﹤0.01%	2907
2016 Q3	$297K	Buy	5,944 +254	+4%	+$10.5K	﹤0.01%	2626
2016 Q2	$241K	Sell	5,690 -241	-4%	-$13.1K	﹤0.01%	2537
2016 Q1	$391K	Buy	5,931 +1,546	+35%	+$80.7K	﹤0.01%	2183
2015 Q4	$273K	Sell	4,385 -877	-17%	-$61.7K	﹤0.01%	2224
2015 Q3	$352K	Sell	5,262 -191	-4%	-$15.6K	﹤0.01%	2076
2015 Q2	$530K	Buy	5,453 +725	+15%	+$69K	﹤0.01%	2069
2015 Q1	$442K	Buy	+4,728	New	+$402K	﹤0.01%	2091

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's MACK Position: Q3 2017 in Review

Raymond James & Associates sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 7,802 shares — an estimated $76K sold.

Raymond James & Associates first reported a position in MACK in Q1 2015 and held it in 10 quarters. The position peaked at $530K in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

Raymond James & Associates reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Raymond James & Associates sold 7,802 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $76K.
Raymond James & Associates first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2015 and held it in 10 quarters.
Raymond James & Associates's Merrimack Pharmaceuticals, Inc. position peaked at $530K in Q2 2015.
73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Raymond James & Associates's 13F filing for Q3 2017, filed 13 Nov 2017.